CoChat

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

Open access
Ziccheddu, Bachisio, Biancon, Giulia, Bagnoli, Filippo, De Philippis, Chiara, Maura, Francesco, Rustad, Even H., Dugo, Matteo, Devecchi, Andrea, De Cecco, Loris, Sensi, Marialuisa, Terragna, Carolina, Martello, Marina, Bagratuni, Tina, Kastritis, Efstathios, Dimopoulos, Meletios A., Cavo, Michele, Carniti, Cristiana, Montefusco, Vittorio, Corradini, Paolo, Bolli, Niccolo · 2020 · Blood Advances
Cited by 78

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

In multiple myeloma, novel treatments with proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs) have prolonged survival but the disease remains incurable. At relapse, next-generation sequencing has shown occasional mutations of drug targets but has failed to identify unifying features that underlie chemotherapy resistance. We studied 42 patients refractory to both PIs and IMiDs. Whole-exome sequencing was performed in 40 patients, and RNA sequencing (RNA-seq) was performed in 27. We found more mutations than were reported at diagnosis and more subclonal mutations, which implies ongoing evolution of the genome of myeloma cells during treatment. The mutational landscape was different from that described in published studies on samples taken at diagnosis. The TP53 pathway was the most frequently inactivated (in 45% of patients). Conversely, point mutations of genes associated with resistance to IMiDs were rare and were always subclonal. Refractory patients were uniquely characterized by having a mutational signature linked to exposure to alkylating agents, whose role in chemotherapy resistance and disease progression remains to be elucidated. RNA-seq analysis showed that treatment or mutations had no influence on clustering, which was instead influenced by karyotypic events. We describe a cluster with both amp(1q) and del(13) characterized by CCND2 upregulation and also overexpression of MCL1, which represents a novel target for experimental treatments. Overall, high-risk features were found in 65% of patients. However, only amp(1q) predicted survival. Gene mutations of IMiD and PI targets are not a preferred mode of drug resistance in myeloma. Chemotherapy resistance of the bulk tumor population is likely attained through differential, yet converging evolution of subclones that are overall variable from patient to patient and within the same patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000779

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 78

Metadata

Authors
Ziccheddu, B., Biancon, G., Bagnoli, F., De Philippis, C., Maura, F., Rustad, E. H., Dugo, M., Devecchi, A., De Cecco, L., Sensi, M., Terragna, C., Martello, M., Bagratuni, T., Kastritis, E., Dimopoulos, M. A., Cavo, M., Carniti, C., Montefusco, V., Corradini, P., & Bolli, N.
Venue
Blood Advances
Published
2020-03-03
Volume
4
Issue
5
Pages
830-844
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3009554897
Cited by
78
References
19
FWCI
7.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000779
The paper
Ziccheddu, B., Biancon, G., Bagnoli, F., De Philippis, C., Maura, F., Rustad, E. H., Dugo, M., Devecchi, A., De Cecco, L., Sensi, M., Terragna, C., Martello, M., Bagratuni, T., Kastritis, E., Dimopoulos, M. A., Cavo, M., Carniti, C., Montefusco, V., Corradini, P., & Bolli, N. (2020). Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000779

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.